LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Selling, General and Administrative Expenses

Last Annual Value

91.14M

3-Year CAGR

176%

5-Year CAGR

85%

10-Year CAGR

124%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses

LENZ · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
91.14M
91.8%33.1%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
42.06M
39.0%27.8%31.0%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
18.37M
14.7%18.4%12.8%
230.12M
69.5%117.9%N/A
15.89M
-10.9%-1.5%-8.7%
159.26M
32.1%39.9%23.8%
171.47M
4.2%11.4%N/A
29.83M
19.6%39.5%N/A
52.35M
6.5%30.3%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01